Tessin Biotechnology

Transcenta, operating as Tessin Biotechnology in China, is a clinical-stage biopharmaceutical company focused on the discovery, development, and manufacturing of antibody-based therapeutics. The company utilizes its proprietary Integrated Continuous Bioprocessing (ICB) platform to achieve high-efficiency, low-cost production of biologics. Its lead candidate, Osemitamab (TST001), is a humanized monoclonal antibody targeting Claudin 18.2, currently undergoing global Phase 3 clinical trials for gastric cancer. Transcenta's pipeline also includes assets for bone diseases, such as the sclerostin inhibitor TST002, and various bispecific antibodies and ADCs for oncology and immunology. Headquartered in Suzhou with facilities in Hangzhou and the United States, the company is listed on the Hong Kong Stock Exchange.